1.62% 1.47

Dopo l'orario di chiusura: 91.97

Revvity Inc (RVTY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché RVTY Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Revvity Inc (RVTY)

Revvity Inc Borsa (RVTY) Ultime notizie

(RVTY) Long Term Investment Analysis - news.stocktradersdaily.com

Revvity gets FDA nod for its automated tuberculosis test - MSN

4 Mass. Rulings You May Have Missed In May - Law360

Revvity (RVTY) Introduces New Mimix Standards for Improved IVD Testing | RVTY Stock News - GuruFocus

New Cancer Testing Standards from Revvity Promise More Accurate Diagnostic Results for Oncology Labs - Stock Titan

Insider Sell: Michelle Mcmurry-heath Sells 600 Shares of Revvity Inc (RVTY) - GuruFocus

Does The Market Have A Low Tolerance For Revvity, Inc.'s (NYSE:RVTY) Mixed Fundamentals? - Yahoo

Millennium Management LLC Trims Position in Revvity, Inc. (NYSE:RVTY) - Defense World

Shareholders in Revvity (NYSE:RVTY) are in the red if they invested three years ago - simplywall.st

Revvity Inc (RVTY) Shares Up 3.52% on May 27 - GuruFocus

Revvity, Inc. (NYSE:RVTY) Shares Purchased by Cetera Investment Advisers - Defense World

RVTY Stock Falls Despite the Latest Launch of Automated Instrument - MSN

Revvity (NYSE:RVTY) Cut to “Hold” at Wall Street Zen - Defense World

Zacks Research Forecasts Revvity’s Q1 Earnings (NYSE:RVTY) - Defense World

Revvity’s EUROIMMUN unveils new fully automated instrument for specialty testing - SelectScience

Enhancing Laboratory Efficiency with Revvity's IDS i20™ Platform - Lab Manager

Is Wall Street Bullish or Bearish on Revvity Stock? - inkl

Is Wall Street Bullish Or Bearish On Revvity Stock? - Barchart.com

Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlo - GuruFocus

Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlook | RVTY Stock News - GuruFocus

Sustainable chemistry in India fueling growth with digital and AI innovation: Revvity Signals - Indian Chemical News

Ameriprise Financial Inc. Increases Stock Position in Revvity, Inc. (NYSE:RVTY) - Defense World

Revvity announces launch of new fully automated instrument for specialty testing - BioSpectrum India

Revvity's EUROIMMUN Unveils New Fully Automated Instrument for S - GuruFocus

Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing | RVTY Stock News - GuruFocus

Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing - Business Wire

Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch

Element Biosciences Welcomes Dr. Madhuri Hegde to its Board of Directors - Business Wire

Revvity Signals Software Inc. v. Cloud Software Group Inc. - Cornerstone Research

Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight - GlobeNewswire Inc.

Shareholders Will Be Pleased With The Quality of Revvity's (NYSE:RVTY) Earnings - Yahoo

Revvity at Bank of America 2025 Healthcare Conference: Navigating Tariffs and Growth - Investing.com India

Revvity To Present At Bank Of America Global Healthcare Conference 2025; Webcast At 12:20 PM ET - Nasdaq

Revvity beats quarterly estimates on steady demand for medical equipment - MSN

Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know - Yahoo Finance

RVTY Q1 Earnings Call: Resilient Performance Amid Academic and Tariff Headwinds, Software and Diagnostics Shine - Yahoo Finance

Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy (NYSE:RVTY) - Seeking Alpha

High Content Screening Market Global Forecasts 2025-2030 - GlobeNewswire

High Content Screening Market Global Forecasts 2025-2030 with Danaher, Revvity, BD, Carl Zeiss, Merck, and Thermo Fisher Scientific Dominating the $2.19 Billion Market - Yahoo Finance

Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - MSN

Revvity Announces Financial Results for the First Quarter of 2025 - ADVFN

Revvity (NYSE:RVTY) Stock Rating Upgraded by UBS Group - Defense World

UBS Upgrades Revvity (BMV:RVTY) - Nasdaq

UBS Upgrades Revvity (BIT:1RVTY) - Nasdaq

UBS lifts Revvity stock rating to Buy, cuts price target to $115 - Investing.com Australia

UBS Upgrades Revvity (LSE:0KHE) - Nasdaq

UBS Upgrades Revvity (RVTY) - Nasdaq

UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | - GuruFocus

UBS lifts Revvity stock rating to Buy, cuts price target to $115 By Investing.com - Investing.com South Africa

UBS Upgrades Revvity to Buy from Neutral, Cuts Price Target to $115 From $145 - marketscreener.com

UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | RVTY Stock News - GuruFocus

Simile a RVTY